Meeting
2016 ASCO Annual Meeting
Plasma cell proliferation by SynKii multiplex immunohistochemistry (mIHC) for clinical use in multiple myeloma (MM).
Authors
Scott Ely
Weill Cornell, New York, NY
Scott Ely , Peter Forsberg , Ruben Niesvizky , Tomer Martin Mark
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 34, 2016 (suppl; abstr 8056)
DOI
10.1200/JCO.2016.34.15_suppl.8056
Abstract #
8056
Poster Bd #
321
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
The prognostic significance of CD45 expression by clonal bone marrow plasma cells in multiple myeloma.
First Author: Wilson I. Gonsalves
Poster
2022 ASCO Annual Meeting
Impact of induction approach on post-stem cell transplant (SCT) outcomes in older adults with newly diagnosed acute myeloid leukemia (AML).
First Author: Faustine Ong
Poster
2020 ASCO Virtual Scientific Program
Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma.
First Author: Stefan Knop
Poster
2016 ASCO Annual Meeting
Dysregulation of nuclear factor-kappaB pathway in multiple myeloma patients at diagnosis and relapse.
First Author: Shivali Jasrotia